ALVAC-CEA vaccine

Last updated

ALVAC-CEA vaccine is a cancer vaccine containing a canary pox virus (ALVAC) combined with the carcinoembryonic antigen (CEA) human gene. [1]

A phase I trial in 118 patients showed safety in humans. [2]

Related Research Articles

Allotransplant is the transplantation of cells, tissues, or organs to a recipient from a genetically non-identical donor of the same species. The transplant is called an allograft, allogeneic transplant, or homograft. Most human tissue and organ transplants are allografts.

Labetuzumab is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. It selectively binds to carcinoembryonic cell adhesion molecule 5.

<span class="mw-page-title-main">Adenosquamous carcinoma</span> Medical condition

Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells and gland-like cells. It has been associated with more aggressive characteristics when compared to adenocarcinoma in certain cancers. It is responsible for 1% to 4% of exocrine forms of pancreas cancer.

An antigen-presenting cell vaccine, or an APC vaccine, is a vaccine made of antigens and antigen-presenting cells (APCs).

Biochemical recurrence is a rise in the blood level of prostate-specific antigen (PSA) in prostate cancer patients after treatment with surgery or radiation. Biochemical recurrence may occur in patients who do not have symptoms. It may mean that the cancer has come back. Also called PSA failure and biochemical relapse.

A chemo-protective agent is any drug that helps to reduce the side- effects of chemotherapy. These agents protect specific body parts from harmful anti-cancer treatments that could potentially cause permanent damage to important bodily tissues. Chemo-protective agents have only recently been introduced as a factor involved with chemotherapy with the intent to assist those cancer patients that require treatment, which as an end result, improves the patients' quality of life.

Tumor board review is conducted when teams of expert physicians meet to review and discuss complex patients with a diagnosis of cancer. It is a treatment planning approach in which a number of doctors who are experts in different medical specialties review and discuss the medical condition and treatment options of a patient. In cancer treatment, a tumor board review may include that of a medical oncologist, a surgical oncologist, and a radiation oncologist.

A consecutive case series is a clinical study that includes all eligible patients identified by the researchers during the study registration period. The patients are treated in the order in which they are identified. This type of study usually does not have a control group.

An enterostomal therapist is a health professional trained in the care of persons with stomas, such as colostomies or urostomies. An enterostomal therapy nurse, or ET nurse, is specialized in treating patients who have ostomies, wounds, or incontinence.

Refractory anemia with excess of blasts (RAEB) is a type of myelodysplastic syndrome with a marrow blast percentage of 5% to 19%.

Syngeneic stem cell transplantation is a procedure in which a patient receives blood-forming stem cells donated by his or her healthy identical twin.

Tumor-associated glycoprotein 72 (TAG-72) is a glycoprotein found on the surface of many cancer cells, including ovary, breast, colon, lung, and pancreatic cancers. It is a mucin-like molecule with a molar mass of over 1000 kDa.

<span class="mw-page-title-main">CEACAM5</span> Mammalian protein found in Homo sapiens

Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e, is a member of the carcinoembryonic antigen (CEA) gene family.

Peritoneal fluid is a serous fluid made by the peritoneum in the abdominal cavity which lubricates the surface of tissue that lines the abdominal wall and pelvic cavity. It covers most of the organs in the abdomen. An increased volume of peritoneal fluid is called ascites.

Ribonucleotide reductase inhibitors are a family of anti-cancer drugs that interfere with the growth of tumor cells by blocking the formation of deoxyribonucleotides.

Vaccine therapy is a type of treatment that uses a substance or group of substances to stimulate the immune system to destroy a tumor or infectious microorganisms such as bacteria or viruses.

An experimental drug is a medicinal product that has not yet received approval from governmental regulatory authorities for routine use in human or veterinary medicine. A medicinal product may be approved for use in one disease or condition but still be considered experimental for other diseases or conditions.

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.

<span class="mw-page-title-main">Lauren V. Wood</span> American allergist, immunologist

Lauren V. Wood is an American allergist, immunologist, and staff physician at the National Cancer Institute (NCI) at the National Institutes of Health (NIH) in Bethesda, Maryland, where she has served as a principal investigator. She is known for conducting studies of vaccines for cancer, Human papillomavirus (HPV), Hepatitis C, and HIV especially for use with children, teens and young adults. She holds the rank of captain in the U.S. Public Health Service (PHS).

<span class="mw-page-title-main">Aimée R. Kreimer</span> American cancer epidemiologist

Aimée Rebecca Kreimer is an American cancer epidemiologist who researches the etiology and prevention of human papillomavirus infection (HPV) and cancer prevention. She is a senior investigator in the infections and immunoepidemiology branch at the National Cancer Institute.

References

  1. "NCI Drug Dictionary". Comprehensive Cancer Information. Retrieved 2024-07-02.
  2. Kaufman, Howard L.; Lenz, Heinz-Josef; Marshall, John; Singh, Deepti; Garett, Chris; Cripps, Christine; Moore, Malcolm; von Mehren, Margaret; Dalfen, Richard; Heim, William J.; Conry, Robert M.; Urba, Walter J.; Benson, Al B.; Yu, Maria; Caterini, Judy; Kim-Schulze, Seunghee; Debenedette, Mark; Salha, Danielle; Vogel, Thorsten; Elias, Ileana; Berinstein, Neil L. (2008). "Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer". Clinical Cancer Research. 14 (15): 4843–4849. doi: 10.1158/1078-0432.CCR-08-0276 . PMID   18676757. S2CID   18152383.

PD-icon.svg This article incorporates public domain material from Dictionary of Cancer Terms. U.S. National Cancer Institute.